{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disease&page=32", "query": { "condition": "Retinal Disease", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 1618, "total_pages": 162, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disease&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disease&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T15:02:53.440Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00469781", "title": "Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cystoid Macular Edema,", "Retinal Thickening" ], "interventions": [ { "name": "2. Xibrom (Bromfenac)", "type": "DRUG" }, { "name": "1. Pred Forte", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Center For Excellence In Eye Care", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2007-05", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2008-09-25", "last_synced_at": "2026-10-24T15:02:53.440Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00469781" }, { "nct_id": "NCT00305630", "title": "Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Choroidal Neovascularization", "Age-Related Macular Degeneration" ], "interventions": [ { "name": "Periocular injection of triamcinolone acetonide 40mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 100, "start_date": "2002-07", "completion_date": "2005-11", "has_results": false, "last_update_posted_date": "2006-03-22", "last_synced_at": "2026-10-24T15:02:53.440Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Portland, Oregon", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00305630" }, { "nct_id": "NCT04469595", "title": "A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Iluvien 0.19 MG Drug Implant", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alimera Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2020-08-31", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-24T15:02:53.440Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Laguna Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04469595" }, { "nct_id": "NCT02022501", "title": "A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "DE-120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 10, "start_date": "2014-01", "completion_date": "2016-04-21", "has_results": false, "last_update_posted_date": "2018-04-18", "last_synced_at": "2026-10-24T15:02:53.440Z", "location_count": 3, "location_summary": "Bakersfield, California • Beverly Hills, California • Dallas, Texas", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02022501" }, { "nct_id": "NCT01940900", "title": "A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "E10030", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" }, { "name": "E10030 sham intravitreal injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ophthotech Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 627, "start_date": "2013-08", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2024-10-30", "last_synced_at": "2026-10-24T15:02:53.440Z", "location_count": 49, "location_summary": "Tucson, Arizona • Fresno, California • La Jolla, California + 43 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01940900" }, { "nct_id": "NCT03922932", "title": "WF and PR OCTA in Diabetic Retinopathy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetic Retinopathy" ], "interventions": [], "intervention_types": [], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 290, "start_date": "2017-08-30", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-10-24T15:02:53.440Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03922932" }, { "nct_id": "NCT02375971", "title": "RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Retinopathy of Prematurity" ], "interventions": [ { "name": "Ranibizumab", "type": "DRUG" }, { "name": "Laser therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 224, "start_date": "2015-12-30", "completion_date": "2017-12-14", "has_results": true, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-10-24T15:02:53.440Z", "location_count": 12, "location_summary": "Loma Linda, California • Sacramento, California • Aurora, Colorado + 9 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02375971" }, { "nct_id": "NCT05407636", "title": "Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "AMD", "nAMD", "Wet Age-related Macular Degeneration", "wAMD", "WetAMD", "CNV" ], "interventions": [ { "name": "ABBV-RGX-314 Dose 1", "type": "GENETIC" }, { "name": "ABBV-RGX-314 Dose 2", "type": "GENETIC" }, { "name": "Aflibercept (EYLEA®)", "type": "BIOLOGICAL" } ], "intervention_types": [ "GENETIC", "BIOLOGICAL" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "50 Years to 89 Years" }, "enrollment_count": 735, "start_date": "2022-01-13", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-10-24T15:02:53.440Z", "location_count": 107, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05407636" }, { "nct_id": "NCT00211471", "title": "Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Severe Diabetic Retinopathy", "Central Retinal Vein Occlusion", "Chronic Inflammation", "Infectious Diseases" ], "interventions": [ { "name": "anecortave acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Manhattan Eye, Ear & Throat Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2002-03", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2007-05-07", "last_synced_at": "2026-10-24T15:02:53.440Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00211471" }, { "nct_id": "NCT00003273", "title": "Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Neuroblastoma", "Retinoblastoma", "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "10 Years", "sex": "ALL", "summary": "Up to 10 Years" }, "enrollment_count": 0, "start_date": "1997-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-12-03", "last_synced_at": "2026-10-24T15:02:53.440Z", "location_count": 17, "location_summary": "Honolulu, Hawaii • Scarborough, Maine • Grand Rapids, Michigan + 11 more", "locations": [ { "city": "Honolulu", "state": "Hawaii" }, { "city": "Scarborough", "state": "Maine" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003273" } ] }